Elevated expression levels of ANXA11, integrins β3 and α3, and TNF-α contribute to a candidate proteomic signature in urine for kidney allograft rejection

Proteomics - Clinical Applications

Volumn 5, Issue 5-6, 2011, Pages 311-321

  Srivastava, Meera ^a   Eidelman, Ofer ^a   Torosyan, Yelizaveta ^a   Jozwik, Catherine ^a   Mannon, Roslyn B ^b,c   Pollard, Harvey B ^a  

^a Uniformed Services University of the Health Sciences   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Graft rejection; Protein arrays; Urine

Indexed keywords

ADAPTOR RELATED PROTEIN COMPLEX 2; ALEMTUZUMAB; ALPHA3 INTEGRIN; ANNEXIN A11; BETA3 INTEGRIN; BIOLOGICAL MARKER; CASPASE 9; CD61 ANTIGEN; DYNAMIN LIKE 1; ESTROGEN RECEPTOR ALPHA; FIBRONECTIN RECEPTOR; INTERLEUKIN 13; MICROTUBULE ASSOCIATED PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYOGENIC FACTOR 3; NITRIC OXIDE SYNTHASE 2A; NUCLEAR AUTOANTIGENIC SPERM PROTEIN; NUCLEAR RECEPTOR NUR77; PLECKSTRIN; PROTEIN; PROTEIN KINASE C LIKE 2; PROTEIN RAD9; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAN BINDING PROTEIN 3; RAPAMYCIN; RHO GTPASE ACTIVATING PROTEIN 1; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 4; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ARTICLE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; GRAFT FAILURE; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEOMICS; QUANTITATIVE ANALYSIS; SCREENING; SIGNAL PROCESSING; URINALYSIS;

ANNEXINS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; GRAFT REJECTION; HUMANS; INTEGRIN ALPHA3; INTEGRIN BETA3; KIDNEY TRANSPLANTATION; MALE; PROTEIN ARRAY ANALYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 79957622287     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000109     Document Type: Article

References (41)

1. Xue, J. L., Daniels, F., Star, R. A., Kimmel, P. L. et al., Incidence and mortality of acute renal failure in medicare beneficiaries, 1992 to 2001. J. Am. Soc. Nephrol. 2006, 17, 1135-1142.
2. Racusen, L. C., The Banff schema and differential diagnosis of allograft dysfunction. Transplant. Proc. 2004, 36, 753-754.
3. Berl, T., American society of nephrology renal research report. J. Am. Soc. Nephrol. 2005, 16, 1886-1903.
4. Schaub, S., Rush, D., Wilkins, J., Gibson, I. W. et al., Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 2004, 1, 219-227.
5. Goldfarb-Rumyantzev, A. S., Naiman, N., Genetic predictors of acute renal transplant rejection. Nephrol. Dial. Transplant 2010, 25, 1039-1047.
6. Hahn, A. B., Kasten-Jolly, J. C., Constantino, D. M., Graffunder, E. et al., TNFalpha, IL-6. IFN-gamma, and IL-10 gene expression polymorphisms and the IL-4 receptor chain vatiant Q576R: effects on renal allograft outcome. Transplantation 2001, 72, 660-665.
7. Dimitrienko, S., Hoar, D. I., Balshaw, N. A., Keown, P. A., Immune response gene polymorphisms in renal transplant recipients. Transplantation. 2005, 80, 1773-1782.
8. Chen, R., Sigdel, T. K., Li, Li., Kambham, N. et al., Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLoS Comput. Biol. 2010, 6, e1000940.
9. Clarke, W., Silverman, B. C., Zhang, Z., Chan, D. W. et al., Characterization of renal allograft rejection by urinary proteomic analysis. Ann. Surg. 2003, 237, 660-665.
10. O'Riordan, E., Goligorsky, M. S., Emerging studies of the urinary proteome: the end of the beginning? Curr. Opin. Nephrol. Hypertens. 2005, 6, 579-585.
11. Parikh, C. R., Jani, A., Mishra, J., Ma, Q. et al., Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant. 2006, 6, 1639-1645.
12. Barratt, J., Topham, P., Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007, 177, 361-368.
13. Bramham, K., Mistry, H. D., Poston, L., Chappell, L. C., Thompson, A. J., The non-invasive biopsy - will urinary proteomics make the renal tissue biopsy redundant? QJM 2009, 102, 523-538.
14. Thomas, C. E., Sexton, W., Benson, K., Sutphen, R. et al., Urine collection and processing for protein biomarker discovery and quantification. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 953-959.
15. Quintana, L. F., Campistol, J. M., Alcolea, M. P., Bañon-Maneus, E. et al., Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol. Cell. Proteomics 2009, 8, 1658-1673.
16. Srivastava, M., Eidelman, O., Jozwik, C., Paweletz, C. et al., Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol. Genet. Metab. 2006, 87, 303-310.
17. Pollard, H. B., Eidelman, O., Jozwik, C., Huang, W. et al., De novo biosynthetic profiling of high abundance proteins in cystic fibrosis lung epithelial cells. Mol. Cell. Proteomics 2006, 5, 1628-1637.
18. Ye, B., Skates, S., Mok, S. C., Horick, N. K. et al., Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 2006, 12, 432-441.
19. Eiján, A. M., Sandes, E., Puricelli, L., Bal De Kier Joffé, E. et al., Cathepsin B levels in urine from bladder cancer patients. Oncol. Rep. 2000, 7, 1395-1399.
20. Girlanda, R., Kleiner, D. E., Duan, Z., Ford, E. A. S., Wright, E. C., Mannon, R. B., Kirk, A. D., Monocyte infiltration and kidney allograft dysfunction during acute rejection. Am. J. Transplant. 2008, 8, 600-607.
21. Paweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L. et al., Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20, 1981-1989.
22. Srivastava, M., Eidelman, O., Zhang, J., Paweletz, C. et al., Digitoxin mimics CFTR-gene therapy, and suppresses hypersecretion of proinflammatory interleukin-8 (IL-8) from cystic fibrosis lung epithelial cells. Proc. Natl. Acad. Sci. USA 2004, C101, 7693-7698.
23. Gyorgy, A. B., Walker, J., Wingo, D., Eidelman, O. et al., Reverse phase protein microarray technology in traumatic brain injury. J. Neurosci. Methods 2010, 192, 96-101.
24. Sugimori, T., Griffith, D. L., Arnaout, M. A., Emerging paradigms of integrin ligand binding and activation. Kidney Int. 1997, 51, 1454-1462.
25. Chandrakanton, A., McDermott, D. H., Tran, H. T. B., Jurewicz, M. et al., Role of β3 integrin in acute renal allograft rejection in humans. Clin. J. Am. Soc. Nephrol. 2007, 2, 1268-1273.
26. Kawaguchi, S., Hemler, M. E., The role of the alpha subunit cytoplasmic domain in regulation of adhesive activity mediated by the integrin VLA-2. J. Biol. Chem. 1993, 268, 16279-16285.
27. Hannigan, G. E., Leung, H. C., Fitz, G. L., Coppolino, M. G. et al., Regulation of cell adhesion and anchorage-dependenjt growth by a new beta 1-integrinh linked protein kinase. Nature 1996, 379, 91-96.
28. Otey, C. A., Vasquez, G. B., Burridge, K., Erickson, B. W., Mapping of the alpha-actinin binding site within the beta 1 integrin cytoplasmic domain. J. Biol. Chem. 1993, 268, 21193-21197.
29. Chen, H. C., AQppeddu, P. A., Parsons, J. T., Hildebrand, J. D. et al., Interaction of focal adhesion kinase with cytoskeletal protein talin. J. Biol. Chem. 1995, 267, 18908-18914.
30. Butcher, E. C., Picker, L. J., Lymphocyte homing and homeostasis. Science 1996, 272, 60-66.
31. Korhonen, M., Yianne, J., Laitinen, L., Virtanen, I., Distribution of beta 1 and beta 3 integrins in human fetal and adult kidney. Lab. Invest. 1990, 62, 616-625.
32. Kreidberg, J. A., Donovan, M. J., Goldstein, S. L., Rennke, H. et al., Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 1996, 122, 3537-3547.
33. Newstead, C. G., Lamb, W. R., Brenchley, P. E., Short, C. D., Serum and urine IL-6 and TNF-alpha in renal transplant recipients with graft dysfunction. Transplantation 1993, 56, 831-835.
34. Darge, S. E., Plasma levels of tumor necrosis factor (TNF) and soluble TNF receptors in kidney transplant recipients. Transplantation 1994, 58, 1000-1008.
35. Kutukculer, N., Shenton, B. K., Clark, K., Rigg, K. M. et al., Renal allograft rejection: the temporal relationship and predictive value of plasma TNF (alpha and beta), IFN-gamma and soluble ICAM-1. Transpl. Int. 1995, 8, 45-50.
36. Morel, D., Normand, E., Lemoine, C., Merlio, J-P. et al., Tumor necrosis factor alpha in human kidney transplant rejection-analysis by in situ hybridization. Transplantation 1993, 55, 773-777.
37. Myśliwiec, M., Balcerska, A., Zorena, K., Myœliwska, J. et al., Serum and urinary cytokine homeostasis and renal tubular function in children with type 1 diabetes mellitus. J. Pediatr. Endocrinol. Metab. 2006, 19, 1421-1427.
38. Yard, B. A., Daha, M. R., Kooymans-Couthino, M., Bruijn, J. A. et al., IL-1a -stimulated TNFa production by cultured human proximal tubular epithelial cells. Kidney. Int. 1992, 42, 383-389.
39. Markoff, A., Gerke, V., Expression and functions of annexins in the kidney. Am. J. Physiol. Renal Physiol. 2005, 289, F949-F956.
40. Cheng, C -W., Rifai, A., Ka, S -M., Shui, H -A. et al., Calcium-binding proteins annexin A2 and S100A6 are sensors of tubular injury and recovery in acute renal failure. Kidney Int. 2005, 68, 2694-2703.
41. Tomas, A., Futter, C., Moss, S. E., Annexin 11 is required for midbody formation and completion in the terminal phase of cytokinesis. J. Cell Biol. 2004, 165, 813-822.